Business Wire

Veristat Appoints Gabriela Rosu, M.D., to Lead Growing Medical Affairs Team

Share

Veristat, the Science-First Full Service CRO and Consultancy, is pleased to announce that Gabriela Rosu, M.D., has joined as Senior Director, Global Medical Affairs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529939891/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Gabriela Rosu, MD Senior Director, Global Medical Affairs Veristat (Photo: Business Wire)

Dr. Rosu is a seasoned professional with over twenty years of experience in scientific and clinical fields, having significantly contributed to the planning and execution of pivotal activities that have led to the approval and commercialization of groundbreaking therapies.

Her appointment is timely, coming just before the American Society of Clinical Oncology’s (ASCO, #ASCO24) Annual Meeting, an event where Dr. Rosu has historically made impactful contributions through numerous abstracts.

Patrick Flanagan, CEO of Veristat, praised Dr. Rosu's dedication, "Dr. Rosu’s fervent commitment to collaboration enhances our ability to make informed decisions, crucially improving patient experiences in clinical trials and ensuring favorable outcomes. Her profound insight into the nuances of oncology therapy development is invaluable, particularly as we continue to focus on optimizing treatment strategies in this area."

Veristat’s Medical Affairs team is at the forefront of evaluating scientific data to address the increasing complexity of biotherapeutic compounds and diverse patient demographics in clinical trials. The team is instrumental in fostering communication and generating essential evidence to support patient safety and optimize treatment outcomes, especially for those with rare and complex diseases (#oncology, #cancer, #raredisease).

In her new role, Dr. Rosu will oversee the global expansion of the medical and safety/pharmacovigilance teams. Her extensive background includes senior medical affairs positions at leading global CROs, where she oversaw medical monitoring for various oncology trials, advised on protocol development, risk mitigation strategies, and strategic development with a focus on patient safety and patient outcomes. Dr. Rosu's experience is particularly notable in immuno-oncology, focusing on managing compound toxicity.

Before transitioning to the CRO industry, Dr. Rosu held significant roles such as Chief Medical Officer at IMV Inc. and Global Medical Advisor at Novo Nordisk Healthcare, where she led clinical developments in oncology and coagulation disorders, among other responsibilities.

Dr. Rosu earned her Doctor of Medicine degree in Romania and has maintained active participation in prestigious organizations such as the American Society for Clinical Oncology (ASCO, #ASCO) and the European Society for Medical Oncology (ESMO, #ESMO).

Reflecting on her new position, Dr. Rosu stated, "I am honored to lead as Senior Director, Global Medical Affairs at Veristat, aligning with the company’s strategic vision to pioneer the development and commercialization of innovative treatments for rare diseases. My dedication to enhancing patient experiences in clinical trials and fostering the development of safe and effective therapies remains unwavering. I look forward to contributing to Veristat’s dynamic team and its noble mission."

About Veristat

Veristat is the Science-First CRO and Consultancy that integrates full service clinical trial execution, regulatory affairs and safety, and strategic advisor services to rapidly advance the development, approval, and commercialization of novel therapies (#NovelTherapies) around the globe. With 30 years of experience solving sponsors' unique and complex clinical, statistical, and regulatory challenges, #Veristat Science-First experts deliver timely, quality-driven results with solutions that are tailored to the needs of patients, clinical trial sites, regulators, sponsor teams, and key stakeholders.

Veristat's focus on novel drug development has led to success when handling any unknown that arises, from the simplest to most complex, across numerous therapeutic areas including rare/ultra-rare disease, advanced therapies, oncology, and biologics including cell and gene therapies (#cellandgenetherapy), enabling sponsors to succeed in extending and saving patients’ lives. Sponsors collaborate with Veristat Science-First experts who care— like they do. It is not just business for Veristat, it’s personal.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Veristat:
Lauren L. Brennan, Vice President of Marketing, Veristat
media@veristat.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Innovative Grid Boosting Technologies Needed to Bring Europe’s Decarbonisation Targets Within Reach, Says New Industry Report20.6.2024 09:00:00 CEST | Press release

CurrENT Europe, the industry association for European innovative grid technology companies, and economic consulting firm Compass Lexecon are releasing a new innovative grid technologies report. Grids are increasingly becoming a bottleneck. Up until now, the transition has been focused on the production side of clean energy generation, but we are now hitting the limits of our grid. The energy transition urgently needs more grid capacity. Electrical transmission and distribution network lengths across Europe need to grow by up to 50% and 60% respectively if we are to see a fully decarbonized power system by 2040. Innovative Grid Technologies (IGTs) can improve grid capacity up to 40%, generating between 100-200GW of extra capacity by 2040. Even a conservative deployment of innovative grid technologies can accelerate transmission grids expansion by 5 to 8 years and distribution grids expansion by 4 to 7 years. Installing IGTs could contribute to the need for network buildout and achieve g

INTRESO Highlights Sustainable Alternatives as EU Considers a Ban on Sulfuryl Fluoride20.6.2024 08:00:00 CEST | Press release

International Treatment Solutions (INTRESO) Group has written to the EU Commission’s Standing Committee on Biocidal Products to highlight the availability of safe, effective and environmentally sustainable alternatives to sulfuryl fluoride, ahead of a 21 June meeting which will consider a ban of the chemical for the preservation treatment of wood [PT8], and as an insecticide and acaricide for the control of insects and arachnids [PT18]. On 21 June, representatives from EU Member States will vote on a proposal to ban the use of sulfuryl fluoride, an extremely harmful synthetic greenhouse gas with a global warming potential more than 4500 times that of carbon dioxide, for these fumigation purposes. In what amounts to an effective ban, the EU is considering withdrawing approvals for the continued biocidal use of sulfuryl fluoride, due to a lack of data on the potential risks to human health posed by the chemical. INTRESO Group produces BLUEFUME™, a highly effective and environmentally sus

GIST Impact, a leading impact data and analytics provider, receives investment from UBS Next20.6.2024 08:00:00 CEST | Press release

Today GIST Impact, the leading provider of impact data and analytics, announced an investment from UBS Next, the leading universal Swiss bank’s venture and innovation unit. GIST Impact delivers actionable impact intelligence to companies and investors, helping them easily measure their environmental and social impacts. The firm’s data and software are founded on a science-based, location-specific and standards-aligned approach, drawing on over 16 years of experience measuring and valuing impact. Its clients include some of the world’s largest banks, sovereign wealth funds, and technology firms. The provision of better impact data is critical in developing greater transparency for investors to help them manage their portfolios. New regulations and standards have also set a higher bar for measuring impact across value chains - whether through assessing impact materiality as part of the Corporate Sustainability Reporting Directive (CSRD) or evaluating natural capital impact as part of the

Grid Dynamics Wins Two MACH Impact Awards for Best Retail Project and Best Overall Change Project19.6.2024 22:05:00 CEST | Press release

Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and advanced analytics services, proudly announces that it has been awarded MACH Impact Awards for Best Retail Project and Best Overall Change Project at the MACH THREE conference, held in New York City on June 17-18, 2024. This annual conference of the MACH Alliance is home of the MACH Impact Awards, honoring MACH (Microservices, API-first, Cloud-native, and Headless) strategies and implementations that solve technical challenges and create rapid return-on-investment. Grid Dynamics’ recognition in two categories is a reflection of its co-innovation with long-time client and global footwear brand, Clarks. The awards highlight Grid Dynamics’ exceptional ability to help clients craft innovative MACH-based solutions that create substantial business impact. “To have the most significant and challenging digital modernisation Clarks has ever undertak

Verimatrix XTD Dashboard Evolves: Revolutionizing Risk Visibility, Tracking, and Actionability19.6.2024 17:45:00 CEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced major enhancements to its XTD dashboard, providing customers with greater visibility into application security risks and more actionable insights to better protect mobile apps and users. First launched in early 2022, the updated XTD dashboard introduces an all new risk classification model that replaces numerical scores with four clear implication classifications -- Informational, Low, Suspicious and High. This allows security teams to quickly understand the severity and context around detected threats. Detailed explanations accompany each risk level, ensuring transparency. In addition to the new risk scoring model, the XTD dashboard provides specific remediation guidance mapped to each risk level. Teams can immediately see recommended steps for investigating, applying protections or addressing vulnerabilities based on the evaluated threat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye